Lawrence D. Kaplan, MD

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in follicular lymphoma.

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib study with combination immune macrophage checkpoint blockade in indolent lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the results of the phase III ECHELON-1 trial in Hodgkin lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses combinations with rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses remaining questions with rituximab (Rituxan) maintenance for patients with mantle cell lymphoma (MCL).